Group 1 - The company announced the convening of its second extraordinary general meeting of shareholders for 2025 on September 4, 2025 [2] - The meeting will review and approve the proposal regarding the reappointment of the internal control auditing accounting firm [2]

证券代码：600833 证券简称：第一医药 公告编号：2025-044 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 9 月 4 日 (二)股东会召开的地点：上海市徐汇区小木桥路 681 号 20 楼第三会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 143 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 112,675,926 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 50.5078 | | 份总数的比例（%） | | 上海第一医药股份有限公司 审议结果：通过 (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 因公司董事长张海波先生另有公务，本次会议由公司副董事长姚军先生主持。 会议采用现场投票及网络投票相结合的方式表决， ...

Core Viewpoint - The legal opinion letter confirms the legality and validity of the procedures, qualifications, proposals, and voting results of the Shanghai First Pharmaceutical Co., Ltd. 2025 Second Extraordinary General Meeting of Shareholders held on September 4, 2025 [1][6]. Group 1: Meeting Summons - The company announced the convening of the 2025 Second Extraordinary General Meeting of Shareholders on August 20, 2025, via the Shanghai Stock Exchange website [3]. - The meeting was scheduled to take place on September 4, 2025, with all necessary details communicated to shareholders 15 days prior [3]. Group 2: Meeting Proceedings - The meeting was held at the designated location, and the voting time was set for the trading hours of September 4, 2025, from 9:15 to 9:25 [3][4]. - Specific voting procedures for margin trading and other related accounts were outlined in accordance with regulatory guidelines [3]. Group 3: Attendance and Voting - A total of 2 shareholders and their representatives attended the meeting, representing 100,854,234 shares with voting rights, which accounted for a significant portion of the total voting shares [4]. - Additionally, 141 shareholders participated in the voting through an online system, with their qualifications verified by the system provider [5]. Group 4: Proposals and Voting Results - The meeting included proposals such as the reappointment of the internal control auditing accounting firm, which were approved by a majority of the voting rights present [5]. - The voting results were announced, confirming that all resolutions passed were in compliance with relevant laws and regulations [5][6]. Group 5: Conclusion - The legal opinion concludes that all aspects of the meeting, including the summons, proceedings, attendance, proposals, and voting, adhered to the applicable laws and the company's articles of association, rendering the resolutions valid [6].

上海市金茂律师事务所 关于上海第一医药股份有限公司 2025 年第二次临时股东会的 法律意见书 致：上海第一医药股份有限公司 （引言） 上海第一医药股份有限公司（以下简称"公司"）2025 年第二次临时股东 会（以下简称"本次股东会"）于 2025 年 9 月 4 日在上海市徐汇区小木桥路 681 号 20 楼第三会议室召开。上海市金茂律师事务所经公司聘请委派韩春燕律 师、路遥律师（以下简称"本所律师"）出席会议，就本次股东会的召集、召开 程序，出席会议人员资格，会议议案，以及会议的表决程序、表决结果等发表法 律意见。 本法律意见书根据《中华人民共和国公司法（2023 修订）》（以下简称"《公 司法》"）、《中华人民共和国证券法（2019 修订）》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《上海证券交易所 上市公司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》（以下简称 "《自律监管指引 1 号》"）等有关法律、法规和规范性文件以及《上海第一医 药股份有限公司章程》（以下简称"《公司章程》"）而出具。 二、 本次股东会的召开 为出具本法律意见书，本所 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.07% on September 4, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the pharmaceutical commercial sector included: - HeFu China (603122) with a closing price of 6.66, up 1.99% [1] - JianZhiJia (605266) at 21.56, up 1.84% [1] - YiXinTang (002727) at 14.98, up 1.70% [1] - Saily Medical (603716) was the biggest loser, closing at 29.00, down 2.26% [2] Trading Volume and Value - The trading volume and value for selected stocks were as follows: - YiXinTang (002727) had a trading volume of 144,800 hands and a transaction value of 216 million [1] - Saily Medical (603716) recorded a trading volume of 256,800 hands with a transaction value of 759 million [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 169 million from institutional investors, while retail investors had a net inflow of 210 million [2] - Key stocks with significant capital flow included: - BaiYang Pharmaceutical (301015) with a net inflow of 15.09 million from institutional investors [3] - LaoBaiXing (603883) with a net inflow of 13.41 million from institutional investors [3]

Group 1 - The company has received a total compensation amount of 56,089,816.67 yuan for the expropriation of three properties located in Huangpu District, Shanghai [2][3] - The properties were previously managed by the company and primarily used for rental operations [2][4] - The compensation agreement has been fully executed, and the company will account for the compensation in its current financial results, which is expected to have a positive impact on the annual operating performance [4] Group 2 - The expropriation will not have a significant impact on the company's business operations [4] - The compensation will be processed according to relevant accounting regulations and will be included in the current profit and loss [4]

Core Points - The pharmaceutical commercial sector experienced a decline of 0.96% on September 3, with First Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 26.14, up 2.27% with a trading volume of 106,600 shares and a transaction value of 279 million [1] - Yifeng Pharmacy (6666609) closed at 24.93, up 2.09% with a trading volume of 203,900 shares and a transaction value of 507 million [1] - Zhejiang Nongyuan (000705) closed at 9.28, up 0.65% with a trading volume of 207,300 shares and a transaction value of 195 million [1] - Guoyao Co. (600511) closed at 29.34, down 0.44% with a trading volume of 40,900 shares and a transaction value of 120 million [1] - Shanghai Pharmaceutical (601607) closed at 18.48, down 0.65% with a trading volume of 202,100 shares and a transaction value of 373 million [1] - Jiuzhoutong (600998) closed at 5.01, down 0.99% with a trading volume of 437,600 shares and a transaction value of 220 million [1] - Nanjing Pharmaceutical (600713) closed at 4.90, down 1.01% with a trading volume of 168,700 shares and a transaction value of 82.85 million [1] - Jianghe Pharmaceutical (002788) closed at 8.40, down 1.18% with a trading volume of 40,400 shares and a transaction value of 34.10 million [1] - Liuyou Group (603368) closed at 17.96, down 1.32% with a trading volume of 61,800 shares and a transaction value of 111 million [1] - Zhongyao Holdings (000950) closed at 5.16, down 1.34% with a trading volume of 162,400 shares and a transaction value of 84.32 million [1] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 295 million from main funds, while speculative funds had a net inflow of 132 million and retail investors had a net inflow of 164 million [3]

Group 1 - The company has received a total compensation amount of 56,089,816.67 yuan for the expropriation of three properties located at Sichuan Middle Road, which were previously managed and rented out by the company [2][3] - The expropriation was conducted by the Shanghai Huangpu District Government, with the properties being assessed by a certified real estate appraisal firm [1] - The company held board meetings and a shareholders' meeting to approve the compensation agreement prior to receiving the funds [2] Group 2 - The expropriated properties were primarily used for rental operations, but the expropriation is not expected to have a significant impact on the company's overall business [3] - The compensation amount will be accounted for in the current financial period, potentially leading to a positive effect on the company's annual operating performance, subject to audit confirmation [3]

一、本次交易概述 证券代码：600833 证券简称：第一医药 公告编号：临 2025-043 上海第一医药股份有限公司 关于收到房屋征收补偿款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 根据上海市黄浦区人民政府《上海市黄浦区人民政府房屋征收决定》（黄府征【2023】 4 号），上海第一医药股份有限公司（以下简称"我司""公司"）位于上海市黄浦区 四川中路 553-555 号、四川中路 545 号、四川中路 639 号三处房屋被纳入征收范围。上 述三处房屋由我司经营管理，曾主要用于对外出租经营使用。本次房屋征收单位为"上 海市黄浦区住房保障和房屋管理局"，房屋征收实施单位为"上海市黄浦第五房屋征收 服务事务所有限公司"，房屋评估单位为"上海房地产估价师事务所有限公司"。 二、对公司的影响 本次被征收的房屋系由我司经营管理，曾主要用于对外出租经营使用。因此本次征 收对公司业务不会产生重大影响。 公司将按照企业会计的相关规定，对上述征收补偿款进行会计处理，计入当期损益。 预计会对公司当年度经营业绩带来一定的积极影响 ...

上海第一医药股份有限公司 2025 年第二次临时股东会 会议资料 二○二五年九月四日 会议资料目录 | 一、2025 年第二次临时股东会会议议程……………………………1 | | --- | | 二、2025 年第二次临时股东会会议须知……………………………2 | | 三、关于聘任财务报告审计会计师事务所的议案……………………5 | | 四、关于续聘内部控制审计会计师事务所的议案……………………8 | - 1 - 上海第一医药股份有限公司 2025 年第二次临时股东会会议议程 会议时间： 现场会议时间：2025 年 9 月 4 日（星期四）下午 14∶00 网络投票起止时间：自 2025 年 9 月 4 日 至 2025 年 9 月 4 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的 投票时间为股东会召开当日的交易时间段，即 9:15-9:25，9:30- 11:30，13:00-15:00；通过互联网投票平台的投票时间为股东会召 开当日的 9:15-15:00。 一、报告现场会议出席情况，宣布公司 2025 年第二次临时股东 会开始 - 2 - 现场会议地点：上海市徐汇区小木桥路 681 号上海外 ...